Ariad to gross up to $345m from stock offer to fund Iclusig commercialization
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals will raise at least $300 million in an offering of 15.3 million common stock shares priced at $19.60 per share to finance sales, manufacturing and distribution of the kinase inhibitor Iclusig (ponatinib), which won US FDA approval on 14 December to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) (scripintelligence.com, 15 December 2012).